Chronic Graft Versus-Host Disease Medications

The average list price of Jakafi (Ruxolitinib) is $17,150.00, but your out of pocket cost will likely be less if you have insurance. Jakafi is covered by some Medicare and insurance plans. This drug is also a limited distribution drug, meaning it is not available at retail pharmacies. Refer to the Key Takeaways for additional information on Jakafi and check our savings tips for other ways to reduce your cost. A generic version of Jakafi is not yet available.

Imbruvica is part of the Kinase Inhibitors class and treats Chronic Graft Versus-Host Disease and Non-Hodgkin Lymphoma. Kinase inhibitors are used to treat cancers such as leukemia, breast cancer, melanoma, lung cancer, and renal cancer. They are also used to prevent organ transplant rejection. They work by stopping cancer cell growth and preventing the spread of the cells. Imbruvica is only available as a brand name drug.

Jakafi XR is part of the JAK Inhibitors class and treats Myelofibrosis, Chronic Graft Versus-Host Disease and Polycythemia Vera. JAK inhibitors are used to treat several different conditions such as rheumatoid arthritis, ulcerative colitis, eczema, and myelofibrosis. They work by blocking the attachment of proteins to their receptors so that the immune system does not over produce inflammation. Jakafi XR is only available as a brand name drug.

BELUMOSUDIL treats graft versus host disease, a condition that can occur after a stem cell transplant. It is prescribed when other medications have not worked well enough. It works by decreasing inflammation. It also prevents the buildup of scar tissue.

Niktimvo is part of the Anti-CSF-1R Antibodies class and treats Chronic Graft Versus-Host Disease. Anti-CSF-1R antibodies, also known as anti-colony stimulating factor 1 receptor antibodies, are used to treat chronic graft versus host disease. They work by reducing the level of inflammatory cells in the body. Niktimvo is only available as a brand name drug.